NAUT vs QTRX
NAUT: Developing a high-throughput, single-molecule proteomics platform designed to unlock the complexity of the human proteome. QTRX: Quanterix develops ultra-sensitive protein detection and spatial tissue analysis platforms for biomarker discovery and early disease diagnostics, with recent FDA breakthrough designation for an Alzheimer's blood test.
Side-by-side fundamentals
| Metric | NAUT | QTRX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $0.977 | $3.48 | |
| Market cap as of 2026-08-03 | $124M | $164M | |
| PEG as of 2026-08-03 | n/a | -0.02 | |
| Net margin as of 2026-08-03 | n/a | -71.9% | |
| Gross margin as of 2026-08-03 | n/a | +44.2% | |
| Operating margin as of 2026-08-03 | n/a | -96.9% | |
| ROE as of 2026-08-03 | -35.0% | -35.2% | NAUT higher |
| ROA as of 2026-08-03 | -29.2% | -26.0% | QTRX higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-03 | n/a | +6.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.6% | |
| Beta as of 2026-08-03 | 1.70 | 1.82 | |
| 1-year return as of 2026-07-31 close | +28.6% | -41.4% | NAUT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.